United Therapeutics Corporation (UTHR)

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), conducted an insider transaction on August 24, 2026, through family trusts. This involved exercising 9,500 stock options at $135.42 per share and simultaneously selling 9,500 common shares at weighted-average prices between $509 and $513. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025.

United Therapeutics (UTHR) CEO Martine A. Rothblatt exercised 9,500 stock options at $135.42 per share and subsequently sold the acquired 9,500 common shares in multiple transactions, with prices ranging from $512.51 to $528.02 per share, on August 21, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, family trusts associated with Rothblatt still hold 84,910 stock options and significant indirect common stock holdings, in addition to her direct holdings of 40,513 shares.

The US FDA has accepted United Therapeutics' New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist for pulmonary arterial hypertension (PAH), setting a PDUFA target action date of June 24, 2027. The filing is supported by Phase III ADVANCE OUTCOMES study results showing ralinepag significantly reduced the risk of clinical worsening events by 55% compared to placebo. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist available for PAH, offering a potential new treatment option.

United Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for ralinepag, a once-daily oral prostacyclin, to treat Pulmonary Arterial Hypertension (PAH). The NDA is supported by positive results from the phase 3 ADVANCE OUTCOMES study, which showed ralinepag significantly reduced the risk of clinical worsening by 55% compared to placebo and improved secondary endpoints like NT-proBNP levels and six-minute walk distance. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027, for its decision.

United Therapeutics (NASDAQ: UTHR) CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares at weighted average prices between $518 and $525 on August 20, 2026. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. After these transactions, the trust retains 94,410 stock options from the grant, and Rothblatt holds additional direct and indirect common shares.